Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments

被引:10
作者
Zhao, Shu-Wu [1 ]
Li, Yi-Ming [2 ]
Li, Yi-Lin [3 ]
Su, Chen [4 ]
机构
[1] Hunan Canc Hosp, Xiangya Sch Med, Dept Anesthesiol, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China
[2] Naval Med Univ, Mil Univ 2, Sch Basic Med Sci, Shanghai 200433, Peoples R China
[3] Hunan Canc Hosp, Xiangya Sch Med, Dept Pathol, Affiliated Canc Hosp, Changsha 410013, Hunan, Peoples R China
[4] Hunan Canc Hosp, Affiliated Canc Hosp, Dept Anesthesiol & Pain, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
Liver injury; COVID-19; Clinical feature; Risk factor; Treatment and management strategy; CORONAVIRUS; OUTCOMES; PREVENTION; MANAGEMENT; INFECTION; PREGNANCY; INSIGHTS; DISEASES; FAILURE; IMPACT;
D O I
10.3748/wjg.v29.i2.241
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The coronavirus disease 2019 (COVID-19) pandemic has been a serious threat to global health for nearly 3 years. In addition to pulmonary complications, liver injury is not uncommon in patients with novel COVID-19. Although the prevalence of liver injury varies widely among COVID-19 patients, its incidence is significantly increased in severe cases. Hence, there is an urgent need to understand liver injury caused by COVID-19. Clinical features of liver injury include detectable liver function abnormalities and liver imaging changes. Liver function tests, computed tomography scans, and ultrasound can help evaluate liver injury. Risk factors for liver injury in patients with COVID-19 include male sex, preexisting liver disease including liver transplantation and chronic liver disease, diabetes, obesity, and hypertension. To date, the mechanism of COVID-19-related liver injury is not fully understood. Its pathophysiological basis can generally be explained by systemic inflammatory response, hypoxic damage, ischemia-reperfusion injury, and drug side effects. In this review, we systematically summarize the existing literature on liver injury caused by COVID-19, including clinical features, underlying mechanisms, and potential risk factors. Finally, we discuss clinical management and provide recommendations for the care of patients with liver injury.
引用
收藏
页码:241 / 256
页数:16
相关论文
共 139 条
[1]   COVID-19 and Liver Injury: A Systematic Review and Meta-Analysis [J].
Ahmed, Jawad ;
Rizwan, Tehlil ;
Malik, Farheen ;
Akhter, Raniyah ;
Malik, Mehreen ;
Ahmad, Junaid ;
Khan, Abdul Wasay ;
Chaudhary, Muhammad A. ;
Usman, Muhammad Shariq .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (07)
[2]   Paediatric gastrointestinal disorders in SARS-CoV-2 infection: Epidemiological and clinical implications [J].
Al-Beltagi, Mohammed ;
Saeed, Nermin Kamal ;
Bediwy, Adel Salah ;
El-Sawaf, Yasser .
WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (16) :1716-1727
[3]  
Alimohamadi Yousef, 2020, J Prev Med Hyg, V61, pE304, DOI 10.15167/2421-4248/jpmh2020.61.3.1530
[4]   Liver injury in COVID-19: The current evidence [J].
Alqahtani, Saleh A. ;
Schattenberg, Joern M. .
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (05) :509-519
[5]   Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19): untangling the knots [J].
Anirvan, Prajna ;
Narain, Sonali ;
Hajizadeh, Negin ;
Aloor, Fuad Z. ;
Singh, Shivaram P. ;
Satapathy, Sanjaya K. .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 :E42-E49
[6]   The effect of canakinumab on clinical outcomes in patients with COVID-19: A meta-analysis [J].
Ao, Guangyu ;
Wang, Yushu ;
Li, Toni ;
Tran, Carolyn ;
Yang, Qing .
JOURNAL OF INFECTION, 2022, 84 (06) :849-851
[7]   Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population [J].
Arleo, Timothy ;
Tong, David ;
Shabto, Julie ;
O'Keefe, Ghazala ;
Khosroshahi, Arezou .
CLINICAL RHEUMATOLOGY, 2021, 40 (07) :2633-2642
[8]   COVID-19: Discovery, diagnostics and drug development [J].
Asselah, Tarik ;
Durantel, David ;
Pasmant, Eric ;
Lau, George ;
Schinazi, Raymond F. .
JOURNAL OF HEPATOLOGY, 2021, 74 (01) :168-184
[9]   Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? [J].
Bailly, Christian ;
Vergoten, Gerard .
PHARMACOLOGY & THERAPEUTICS, 2020, 214
[10]   Abdominal imaging in COVID-19 [J].
Balaban, Daniel Vasile ;
Baston, Oana Madalina ;
Jinga, Mariana .
WORLD JOURNAL OF RADIOLOGY, 2021, 13 (07) :227-232